E Reigadas1, L Alcalá2, M Valerio3, M Marín4, A Martin5, E Bouza4. 1. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain helenrei@hotmail.com. 2. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain. 3. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain. 4. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain Medicine Department, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid, Spain. 5. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Abstract
OBJECTIVES: Prediction of patients with poor outcome is necessary in order to plan the proper management of Clostridium difficile infection (CDI); however, clinical criteria are insufficient. In a previous study, we observed that high toxigenic C. difficile cfu stool counts at diagnosis were associated with a poor outcome. Our objective was to investigate the role of the PCR toxin B amplification cycle threshold (Ct) in the prediction of CDI poor outcome and to derive and validate a high-risk prediction rule using this marker. METHODS: We prospectively included patients with CDI (derivation cohort, January 2013 to June 2014; and validation cohort, December 2014 to May 2015), who were followed for at least 2 months after their last episode/recurrence. All samples were tested with Xpert™ C. difficile. RESULTS: For the derivation cohort (n = 129) toxin B Ct was independently associated with poor outcome (P < 0.001). The receiver operating characteristic (ROC) curve yielded an AUC of 0.816. Using a cut-off of <23.5 cycles for high risk of poor outcome, the diagnostic accuracy was 81.4%, the sensitivity was 46.5% (95% CI 32.5-61.1) and the specificity was 98.8% (95% CI 93.7-99.8). For the validation cohort (n = 170), the diagnostic accuracy was 81.8%, the sensitivity was 88.4% (95% CI 75.5-94.9) and the specificity was 79.5% (95% CI 71.7-85.6). The ROC curve yielded an AUC of 0.857. CONCLUSIONS: Low toxin B Ct values from samples collected at the initial moment of diagnosis appears to be a strong marker for poor outcome. This available test may identify, at an early stage, patients who are at higher risk of a poor outcome CDI.
OBJECTIVES: Prediction of patients with poor outcome is necessary in order to plan the proper management of Clostridium difficile infection (CDI); however, clinical criteria are insufficient. In a previous study, we observed that high toxigenic C. difficile cfu stool counts at diagnosis were associated with a poor outcome. Our objective was to investigate the role of the PCR toxin B amplification cycle threshold (Ct) in the prediction of CDI poor outcome and to derive and validate a high-risk prediction rule using this marker. METHODS: We prospectively included patients with CDI (derivation cohort, January 2013 to June 2014; and validation cohort, December 2014 to May 2015), who were followed for at least 2 months after their last episode/recurrence. All samples were tested with Xpert™ C. difficile. RESULTS: For the derivation cohort (n = 129) toxin B Ct was independently associated with poor outcome (P < 0.001). The receiver operating characteristic (ROC) curve yielded an AUC of 0.816. Using a cut-off of <23.5 cycles for high risk of poor outcome, the diagnostic accuracy was 81.4%, the sensitivity was 46.5% (95% CI 32.5-61.1) and the specificity was 98.8% (95% CI 93.7-99.8). For the validation cohort (n = 170), the diagnostic accuracy was 81.8%, the sensitivity was 88.4% (95% CI 75.5-94.9) and the specificity was 79.5% (95% CI 71.7-85.6). The ROC curve yielded an AUC of 0.857. CONCLUSIONS: Low toxin B Ct values from samples collected at the initial moment of diagnosis appears to be a strong marker for poor outcome. This available test may identify, at an early stage, patients who are at higher risk of a poor outcome CDI.
Authors: Julia Origüen; María Ángeles Orellana; Mario Fernández-Ruiz; Laura Corbella; Rafael San Juan; María Ruiz-Ruigómez; Francisco López-Medrano; Manuel Lizasoain; Tamara Ruiz-Merlo; Guillermo Maestro-de la Calle; Patricia Parra; Jennifer Villa; Rafael Delgado; José María Aguado Journal: J Clin Microbiol Date: 2019-01-30 Impact factor: 5.948
Authors: Mini Kamboj; Jennifer Brite; Tracy McMillen; Elizabeth Robilotti; Alejandro Herrera; Kent Sepkowitz; N Esther Babady Journal: J Infect Date: 2017-12-08 Impact factor: 6.072
Authors: Nira R Pollock; Alice Banz; Xinhua Chen; David Williams; Hua Xu; Christine A Cuddemi; Alice X Cui; Matthew Perrotta; Eaman Alhassan; Brigitte Riou; Aude Lantz; Mark A Miller; Ciaran P Kelly Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079
Authors: Carolyn D Alonso; Ciarán P Kelly; Kevin W Garey; Anne J Gonzales-Luna; David Williams; Kaitlyn Daugherty; Christine Cuddemi; Javier Villafuerte-Gálvez; Nicole C White; Xinhua Chen; Hua Xu; Rebecca Sprague; Caitlin Barrett; Mark Miller; Agnès Foussadier; Aude Lantz; Alice Banz; Nira R Pollock Journal: Clin Infect Dis Date: 2022-07-06 Impact factor: 20.999
Authors: Mark I Garvey; Craig W Bradley; Martyn A C Wilkinson; Elisabeth Holden Journal: Antimicrob Resist Infect Control Date: 2017-12-19 Impact factor: 4.887
Authors: Sixto M Leal; Elena B Popowitch; Kara J Levinson; Teny M John; Bethany Lehman; Maria Bueno Rios; Peter H Gilligan; Melissa B Miller Journal: J Clin Microbiol Date: 2018-05-25 Impact factor: 5.948
Authors: Salvador López-Cárdenas; Eva Torres-Martos; Juan Mora-Delgado; Juan Manuel Sánchez-Calvo; Marta Santos-Peña; Ángel Zapata López; María Dolores López-Prieto; Salvador Pérez-Cortés; Juan Carlos Alados Journal: Gut Microbes Date: 2021-03-04